4 research outputs found
Evaluation of circulating miR-21 and miR-222 as diagnostic biomarkers for gastric cancer
Introduction: Gastric cancer is responsible for a large number of death worldwide and its high death rate is associated with a lack of noninvasive tools in GC diagnosis. MicroRNAs (miRNAs), as gene regulators, were shown to dysregulate in different types of cancer. Moreover, it is proven that miRNAs are stable in serum/plasma, so they can be used as a potential noninvasive marker in GC diagnosis. The objective of this study is to investigate the plasma miRNA expression in GC samples compared to controls as a potential biomarker in cancer diagnosis.
Materials and Methods: Expression levels of miR-21 and miR-222 were assessed using quantitative real-time polymerase chain reaction in plasma of 30 GC patients and 30 healthy controls. Diagnostic value of selected miRNAs was evaluated using receiver operating characteristic curve. Target prediction was done using bioinformatics tools to investigate the signaling pathways and function of the selected miRNAs.
Results: Our results demonstrated that the expression levels of miR-21 and miR-222 were significantly higher in GC plasma than in the controls (P < 0.0001, P = 0.043). The sensitivity and specificity for miR-21 and in plasma were 86.7% and 72.2% and for miR-222 were 62.5% and 56.2%, respectively. Bioinformatics analysis revealed that most target genes of miR-21 and miR-222 are involved in cancer-related signaling pathway such as tumor initiation and progression.
Conclusion: Our results indicated that miR-21 and miR-222 in plasma samples can be served as a potential noninvasive tool in GC detection. Furthermore, the miRNA target prediction manifested that miR-21 and miR-222 involve in key processes associated with GC initiation and development
A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is currently spreading
and mutating with increasing speed worldwide. Therefore, there is an urgent need for a simple,
sensitive, and high-throughput (HTP) assay to quantify virus–host interactions in order to quickly
evaluate the infectious ability of mutant viruses and to develop or validate virus-inhibiting drugs.
Here, we developed an ultrasensitive bioluminescent biosensor to evaluate virus–cell interactions
by quantifying the interaction between the SARS-CoV-2 receptor binding domain (RBD) and its
cellular receptor angiotensin-converting enzyme 2 (ACE2) both in living cells and in vitro. We have
successfully used this novel biosensor to analyze SARS-CoV-2 RBD mutants and evaluated candidate
small molecules (SMs), antibodies, and peptides that may block RBD:ACE2 interaction. This simple,
rapid, and HTP biosensor tool will significantly expedite the detection of viral mutants and the
anti-COVID-19 drug discovery process.Medicine, Faculty ofNon UBCMedicine, Department ofNeurology, Division ofReviewedFacult